Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordisk’s new weight-loss pill is quickly moving ahead of Eli Lilly’s competitor, and experts say the reason is simple: doctors trust what they already know. Even though Eli Lilly launched its own pill, Foundayo, soon after Novo Nordisk introduced…
Europe’s top drug regulator has moved closer to approving a daily weight-loss pill. The Committee for Medicinal Products for Human Use (CHMP), operating under the European Medicines Agency (EMA), issued a positive opinion for once-daily oral semaglutide 25 mg, sold…
The oral glucagon-like peptide-1 (GLP-1) weight-loss market is entering a period of rapid expansion. In view of this, GlobalData forecasts weight-loss pill revenues will rise to $34.3 billion. To be precise, this growth will disrupt traditional retail food and beverage…